Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

12.12USD
6:07pm BST
Change (% chg)

$-0.44 (-3.50%)
Prev Close
$12.56
Open
$12.43
Day's High
$12.63
Day's Low
$11.95
Volume
3,410
Avg. Vol
8,414
52-wk High
$16.59
52-wk Low
$8.80

Select another date:

Tue, May 15 2018

BRIEF-Summit Therapeutics Files For Mixed Shelf Of Upto $225 Million

* SUMMIT THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source http://bit.ly/2jXftRN Further company coverage:

BRIEF-Summit Therapeutics Says Proposed Placing To Raise Up To 15 Mln Stg

* ‍ANNOUNCES A PROPOSED PLACING TO RAISE UP TO £15.0 MILLION​

BRIEF-Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics With Potential In Global Fight Against Gonorrhoea

* SUMMIT’S INFECTIOUS DISEASES TECHNOLOGY PLATFORM YIELDS NOVEL ANTIBIOTICS WITH POTENTIAL IN GLOBAL FIGHT AGAINST GONORRHOEA

BRIEF-Summit Expands Enrolment In Phaseout DMD Phase 2 Clinical Trial To Include Planned Additional Group

* SUMMIT EXPANDS ENROLMENT IN PHASEOUT DMD PHASE 2 CLINICAL TRIAL TO INCLUDE PLANNED ADDITIONAL GROUP Source text for Eikon: Further company coverage:

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

BRIEF-Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios

* SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA

Select another date: